Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amneal Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports First Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report First Quarter 2023 Results on May 5, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces Strategic European Partnership with Orion Corporation
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Third Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives FDA Approval for Leuprolide Acetate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Third Quarter 2022 Results on November 4, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal launches 4 new Generic products, including Vasopressin single-dose
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Second Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Appoints Deborah M. Autor to Board of Directors
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Second Quarter 2022 Results on August 5, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at the 2022 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conferences in May
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.